Johann Morelle
@johannmorelle.bsky.social
MD, PhD, FASN | Head of the Division of Nephrology at University Hospitals Namur (www.chuuclnamur.be) | Associate Professor of Nephrology | Physician-scientist at de Duve Institute (www.deduveinstitute.be)
Special interest in glomerular diseases and TMA
Special interest in glomerular diseases and TMA
Reposted by Johann Morelle
Stream it now! Our webinar in cooperation with NDT:
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
YouTube video by MARKUS at HOMe
youtu.be
October 31, 2025 at 6:21 PM
Stream it now! Our webinar in cooperation with NDT:
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
Reposted by Johann Morelle
Thrilled to have this finally published! If you are interested in learning about the collagen IV diseases Gould syndrome and Alport syndrome, add this to your reading list. www.nature.com/articles/s41...
Collagen IV in Gould syndrome and Alport syndrome
Nature Reviews Nephrology - In this Review, the authors focus on the role of collagen IV in Gould syndrome and Alport syndrome. They discuss the molecular and phenotypic similarities and...
www.nature.com
July 31, 2025 at 2:44 PM
Thrilled to have this finally published! If you are interested in learning about the collagen IV diseases Gould syndrome and Alport syndrome, add this to your reading list. www.nature.com/articles/s41...
Reposted by Johann Morelle
🧬Introducing our first-ever handbook of genetic nephrology, with free download until 8/2025
authors.elsevier.com/a/1lSgWzcYo6...
@andrewmallett8.bsky.social and I saw a gap in foundational reading of genetic nephrology and decided to gather articles that clinician and learners can all enjoy
authors.elsevier.com/a/1lSgWzcYo6...
@andrewmallett8.bsky.social and I saw a gap in foundational reading of genetic nephrology and decided to gather articles that clinician and learners can all enjoy
authors.elsevier.com
July 19, 2025 at 3:37 PM
🧬Introducing our first-ever handbook of genetic nephrology, with free download until 8/2025
authors.elsevier.com/a/1lSgWzcYo6...
@andrewmallett8.bsky.social and I saw a gap in foundational reading of genetic nephrology and decided to gather articles that clinician and learners can all enjoy
authors.elsevier.com/a/1lSgWzcYo6...
@andrewmallett8.bsky.social and I saw a gap in foundational reading of genetic nephrology and decided to gather articles that clinician and learners can all enjoy
Reposted by Johann Morelle
We got it 💪🏻 #ERA25 thank you @rosertorra.bsky.social 👏🏻
June 7, 2025 at 1:06 PM
We got it 💪🏻 #ERA25 thank you @rosertorra.bsky.social 👏🏻
Reposted by Johann Morelle
Finding novel antigens in membranous nephropathy through mass spectrometry by @johannmorelle.bsky.social #ERA25
June 6, 2025 at 3:10 PM
Finding novel antigens in membranous nephropathy through mass spectrometry by @johannmorelle.bsky.social #ERA25
Reposted by Johann Morelle
The first #ERA25 simultaneous pub
CONFIDENCE trial of empagliflozin + finerenone in N = 579
Greater reduction in ACR and BP
Note the impressive GFR dip
www.nejm.org/doi/full/10....
CONFIDENCE trial of empagliflozin + finerenone in N = 579
Greater reduction in ACR and BP
Note the impressive GFR dip
www.nejm.org/doi/full/10....
June 5, 2025 at 9:54 AM
The first #ERA25 simultaneous pub
CONFIDENCE trial of empagliflozin + finerenone in N = 579
Greater reduction in ACR and BP
Note the impressive GFR dip
www.nejm.org/doi/full/10....
CONFIDENCE trial of empagliflozin + finerenone in N = 579
Greater reduction in ACR and BP
Note the impressive GFR dip
www.nejm.org/doi/full/10....
Reposted by Johann Morelle
Congrats to all the @asnkidney.bsky.social lifetime and mid-career awardees!
@ksusztak.bsky.social @genetickidneydoc.bsky.social @shinamenon.bsky.social @michellejtx.bsky.social and everyone else!
@ksusztak.bsky.social @genetickidneydoc.bsky.social @shinamenon.bsky.social @michellejtx.bsky.social and everyone else!
June 3, 2025 at 7:13 PM
Congrats to all the @asnkidney.bsky.social lifetime and mid-career awardees!
@ksusztak.bsky.social @genetickidneydoc.bsky.social @shinamenon.bsky.social @michellejtx.bsky.social and everyone else!
@ksusztak.bsky.social @genetickidneydoc.bsky.social @shinamenon.bsky.social @michellejtx.bsky.social and everyone else!
Reposted by Johann Morelle
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
bit.ly/4ccCs4H #OpenAccess
#VisualAbstract
bit.ly/4ccCs4H #OpenAccess
#VisualAbstract
May 24, 2025 at 10:01 PM
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
bit.ly/4ccCs4H #OpenAccess
#VisualAbstract
bit.ly/4ccCs4H #OpenAccess
#VisualAbstract
Reposted by Johann Morelle
Complement activation in secondary thrombotic microangiopathies
doi.org/10.1093/ndt/...
👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy
doi.org/10.1093/ndt/...
👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy
May 15, 2025 at 7:18 PM
Complement activation in secondary thrombotic microangiopathies
doi.org/10.1093/ndt/...
👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy
doi.org/10.1093/ndt/...
👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy
Secondary #TMA represent a major unmet medical need.
Grateful for the opportunity to review the role of #complement and discuss when to consider complement inhibitors in these dramatic diseases.
🙏 to outstanding co-authors and the #ERA IWG
@kronbichlerlab.bsky.social
@ndt-era.bsky.social
Grateful for the opportunity to review the role of #complement and discuss when to consider complement inhibitors in these dramatic diseases.
🙏 to outstanding co-authors and the #ERA IWG
@kronbichlerlab.bsky.social
@ndt-era.bsky.social
Complement activation in secondary thrombotic microangiopathies
doi.org/10.1093/ndt/...
👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy
doi.org/10.1093/ndt/...
👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy
May 16, 2025 at 4:09 AM
Secondary #TMA represent a major unmet medical need.
Grateful for the opportunity to review the role of #complement and discuss when to consider complement inhibitors in these dramatic diseases.
🙏 to outstanding co-authors and the #ERA IWG
@kronbichlerlab.bsky.social
@ndt-era.bsky.social
Grateful for the opportunity to review the role of #complement and discuss when to consider complement inhibitors in these dramatic diseases.
🙏 to outstanding co-authors and the #ERA IWG
@kronbichlerlab.bsky.social
@ndt-era.bsky.social
Reposted by Johann Morelle
Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism"
—the 1st human to undergo custom genome editing
—from decades of NIH funded research
www.nejm.org/doi/full/10....
@nejm.org
www.nejm.org/doi/full/10....
www.nytimes.com/2025/05/15/h...
—the 1st human to undergo custom genome editing
—from decades of NIH funded research
www.nejm.org/doi/full/10....
@nejm.org
www.nejm.org/doi/full/10....
www.nytimes.com/2025/05/15/h...
May 15, 2025 at 6:05 PM
Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism"
—the 1st human to undergo custom genome editing
—from decades of NIH funded research
www.nejm.org/doi/full/10....
@nejm.org
www.nejm.org/doi/full/10....
www.nytimes.com/2025/05/15/h...
—the 1st human to undergo custom genome editing
—from decades of NIH funded research
www.nejm.org/doi/full/10....
@nejm.org
www.nejm.org/doi/full/10....
www.nytimes.com/2025/05/15/h...
Reposted by Johann Morelle
Beautiful essay from Rajeev Raghavan in the @nejm.org
Driving Jackson (a dialysis patient to his clinic appointments)
www.nejm.org/doi/full/10....
#NephSky
Driving Jackson (a dialysis patient to his clinic appointments)
www.nejm.org/doi/full/10....
#NephSky
Driving Jackson | NEJM
When a low-income patient receiving home dialysis misses the bus to the clinic, his
nephrologist makes a decision that launches a long-term relationship and brings unexpected
meaning into his own life...
www.nejm.org
May 11, 2025 at 2:51 AM
Beautiful essay from Rajeev Raghavan in the @nejm.org
Driving Jackson (a dialysis patient to his clinic appointments)
www.nejm.org/doi/full/10....
#NephSky
Driving Jackson (a dialysis patient to his clinic appointments)
www.nejm.org/doi/full/10....
#NephSky
Reposted by Johann Morelle
In an article within the #ASNJASN series, Mechanisms of Kidney Diseases, authors examine the link between gold salts, penicillamine, and mercury and membranous nephropathy, aiming to develop new hypotheses on how these substances may promote immune dysregulation. https://bit.ly/JASN0719
May 7, 2025 at 5:00 PM
In an article within the #ASNJASN series, Mechanisms of Kidney Diseases, authors examine the link between gold salts, penicillamine, and mercury and membranous nephropathy, aiming to develop new hypotheses on how these substances may promote immune dysregulation. https://bit.ly/JASN0719
Reposted by Johann Morelle
The whole story is surreally fascinating
Tim Friede’s YT channel: youtube.com/@timfriede57...
The @cellpress.bsky.social paper: www.cell.com/cell/fulltex...
A BBC story www.bbc.com/news/article...
A universal antivenom would be huge - this seems like a big step
Tim Friede’s YT channel: youtube.com/@timfriede57...
The @cellpress.bsky.social paper: www.cell.com/cell/fulltex...
A BBC story www.bbc.com/news/article...
A universal antivenom would be huge - this seems like a big step
May 3, 2025 at 1:01 PM
The whole story is surreally fascinating
Tim Friede’s YT channel: youtube.com/@timfriede57...
The @cellpress.bsky.social paper: www.cell.com/cell/fulltex...
A BBC story www.bbc.com/news/article...
A universal antivenom would be huge - this seems like a big step
Tim Friede’s YT channel: youtube.com/@timfriede57...
The @cellpress.bsky.social paper: www.cell.com/cell/fulltex...
A BBC story www.bbc.com/news/article...
A universal antivenom would be huge - this seems like a big step
Reposted by Johann Morelle
Some take home messages from an inspiring talk by @nephrorock.bsky.social at @kidneycon.bsky.social !
May 3, 2025 at 4:11 AM
Some take home messages from an inspiring talk by @nephrorock.bsky.social at @kidneycon.bsky.social !
Reposted by Johann Morelle
🔥 Happening tonight #nephjc
Tomorrow 4/29/25 at 9pm EST #NephSky on #Bluesky
🔬Renal pathologist house call!
🔥 Isolated microvascular inflammation 🔥 in kidney transplant recipients & the new Banff 2022 criteria. Read the summary here by @dramiliflores.bsky.social & @glombandit.bsky.social:
www.nephjc.com/news/mvi-allografts
🔬Renal pathologist house call!
🔥 Isolated microvascular inflammation 🔥 in kidney transplant recipients & the new Banff 2022 criteria. Read the summary here by @dramiliflores.bsky.social & @glombandit.bsky.social:
www.nephjc.com/news/mvi-allografts
Kidney Allografts-Play With Fire, Get Burned — NephJC
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study co...
www.nephjc.com
April 29, 2025 at 8:22 AM
🔥 Happening tonight #nephjc
🔥 Final (pdf) version available online (free):
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
@ajkd.bsky.social
➡️ doi.org/10.1053/j.aj...
#OpenAccess
🙏 to all collaborators and sponsors!
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
@ajkd.bsky.social
➡️ doi.org/10.1053/j.aj...
#OpenAccess
🙏 to all collaborators and sponsors!
April 29, 2025 at 7:47 AM
🔥 Final (pdf) version available online (free):
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
@ajkd.bsky.social
➡️ doi.org/10.1053/j.aj...
#OpenAccess
🙏 to all collaborators and sponsors!
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
@ajkd.bsky.social
➡️ doi.org/10.1053/j.aj...
#OpenAccess
🙏 to all collaborators and sponsors!
Reposted by Johann Morelle
In the Advance-HTN phase 2b trial of the aldosterone synthase inhibitor lorundrostat in participants with uncontrolled hypertension, lorundrostat was associated with greater reductions in blood pressure than placebo. Full trial results: nej.md/4ipbCIf
#MedSky #CardioSky
#MedSky #CardioSky
April 23, 2025 at 9:12 PM
In the Advance-HTN phase 2b trial of the aldosterone synthase inhibitor lorundrostat in participants with uncontrolled hypertension, lorundrostat was associated with greater reductions in blood pressure than placebo. Full trial results: nej.md/4ipbCIf
#MedSky #CardioSky
#MedSky #CardioSky
Reposted by Johann Morelle
The ASIs have arrived
www.nejm.org/doi/full/10....
Aldosterone synthase inhibitors - first one to finish the phase 3 line
#Lorundrostat #Hypertension
www.nejm.org/doi/full/10....
Aldosterone synthase inhibitors - first one to finish the phase 3 line
#Lorundrostat #Hypertension
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM
Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...
www.nejm.org
April 23, 2025 at 10:01 PM
The ASIs have arrived
www.nejm.org/doi/full/10....
Aldosterone synthase inhibitors - first one to finish the phase 3 line
#Lorundrostat #Hypertension
www.nejm.org/doi/full/10....
Aldosterone synthase inhibitors - first one to finish the phase 3 line
#Lorundrostat #Hypertension
Reposted by Johann Morelle
Why you should know your viral exposure status (i.e CMV) if you're going to undergo immunotherapy for cancer (but almost no one knows)
www.nature.com/articles/s41...
www.nature.com/articles/s41...
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade - Nature Medicine
Analysis of multiple cohorts of patients with melanoma demonstrates a positive association between cytomegalovirus serostatus and overall survival in patients treated with monotherapy but not combinat...
www.nature.com
April 24, 2025 at 12:43 AM
Why you should know your viral exposure status (i.e CMV) if you're going to undergo immunotherapy for cancer (but almost no one knows)
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Johann Morelle
EKFC equation to estimate GFR from creatinine and cystatin C, you freely use this link
ekfccalculator.pages.dev
ekfccalculator.pages.dev
ekfccalculator.pages.dev
April 21, 2025 at 11:29 AM
EKFC equation to estimate GFR from creatinine and cystatin C, you freely use this link
ekfccalculator.pages.dev
ekfccalculator.pages.dev
Reposted by Johann Morelle
Sparsentan as First-Line Treatment of Incident Patients with IgAN: Interim Analysis of the SPARTAN Trial
#Nephpearls #NKFClinicals 🇺🇸 #NephSky
📌 The rapid reduction of u-sCD163 levels is the first demonstration of SPAR’s anti-inflammatory effect in humans and supports preclinical data
#Nephpearls #NKFClinicals 🇺🇸 #NephSky
📌 The rapid reduction of u-sCD163 levels is the first demonstration of SPAR’s anti-inflammatory effect in humans and supports preclinical data
April 15, 2025 at 1:17 AM
Sparsentan as First-Line Treatment of Incident Patients with IgAN: Interim Analysis of the SPARTAN Trial
#Nephpearls #NKFClinicals 🇺🇸 #NephSky
📌 The rapid reduction of u-sCD163 levels is the first demonstration of SPAR’s anti-inflammatory effect in humans and supports preclinical data
#Nephpearls #NKFClinicals 🇺🇸 #NephSky
📌 The rapid reduction of u-sCD163 levels is the first demonstration of SPAR’s anti-inflammatory effect in humans and supports preclinical data
Reposted by Johann Morelle
DUPLEX Posthoc: Antiproteinuric and nephroprotective benefits of Sparsentan in patients with FSGS
#Nephpearls #NKFClinicals 🇺🇸 #NephSky
#Nephpearls #NKFClinicals 🇺🇸 #NephSky
April 11, 2025 at 4:38 AM
DUPLEX Posthoc: Antiproteinuric and nephroprotective benefits of Sparsentan in patients with FSGS
#Nephpearls #NKFClinicals 🇺🇸 #NephSky
#Nephpearls #NKFClinicals 🇺🇸 #NephSky
Reposted by Johann Morelle
PARASOL ☂️: Achieving proteinuria <0.7 g/g is associated with meaningful reduction in kidney failure risk in FSGS
#Nephpearls #NKFClinicals #NephSky
#Nephpearls #NKFClinicals #NephSky
April 11, 2025 at 4:54 AM
PARASOL ☂️: Achieving proteinuria <0.7 g/g is associated with meaningful reduction in kidney failure risk in FSGS
#Nephpearls #NKFClinicals #NephSky
#Nephpearls #NKFClinicals #NephSky
Reposted by Johann Morelle
April 11, 2025 at 5:00 AM